Pegapamodutide - Transition Therapeutics

Drug Profile

Pegapamodutide - Transition Therapeutics

Alternative Names: LY2944876; OPK 88003; Oxyntomodulin analog - Eli Lilly; TT-401

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; OPKO Health; Transition Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 11 Jun 2018 OPKO Health completes enrolment in its phase IIb trial for Type 2 diabetes and Obesity in the US
  • 11 Jun 2018 OPKO Health plans a phase III trial for Type 2 diabetes and Obesity
  • 23 Mar 2018 OPKO Health initiates enrolment in a phase IIb trial for Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top